BC1D14, also known as Butyryl-CoA dehydrogenase-like protein (BCD), is a key enzyme involved in the regulation of fatty acid metabolism and energy production within the cell. Its primary function is to catalyze the conversion of butyryl-CoA to crotonyl-CoA, a crucial step in the beta-oxidation pathway of fatty acid catabolism. By facilitating this reaction, BC1D14 contributes to the breakdown of fatty acids to generate acetyl-CoA, which can subsequently enter the tricarboxylic acid (TCA) cycle for ATP production. Additionally, BC1D14 is involved in the regulation of ketone body metabolism, particularly in ketogenesis, where it participates in the conversion of acetoacetate to acetoacetyl-CoA, an essential step in ketone body synthesis during periods of fasting or prolonged exercise.
The activation of BC1D14 is tightly regulated to maintain metabolic homeostasis and ensure proper energy production within the cell. One of the primary mechanisms of BC1D14 activation is through allosteric regulation by metabolites such as acetyl-CoA and NADH, which serve as cofactors or substrates in the enzymatic reaction catalyzed by BC1D14. Increased levels of these metabolites signal cellular energy abundance and promote the activation of BC1D14, thereby enhancing fatty acid oxidation and ketogenesis to meet energy demands. Furthermore, BC1D14 activity can be modulated by post-translational modifications, such as phosphorylation, acetylation, and ubiquitination, which regulate its enzymatic activity, stability, and subcellular localization. Activation of signaling pathways involved in cellular energy sensing, such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs), can also promote BC1D14 activation, further coordinating fatty acid metabolism and energy homeostasis in response to cellular energy status. Overall, the activation of BC1D14 is governed by a complex interplay of metabolic signals, post-translational modifications, and signaling pathways, ensuring efficient regulation of fatty acid metabolism and energy production in the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, an L-type calcium channel blocker, enhances BC1D14 activity indirectly through calcium-dependent signaling pathways. By inhibiting calcium influx, it stimulates these pathways that BC1D14 is directly involved in, leading to its functional activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of cyclic nucleotide phosphodiesterases (PDEs). It enhances BC1D14 activity by increasing the accumulation of cAMP and cGMP in cells. These cyclic nucleotides activate PKA and PKG pathways, respectively, which phosphorylate BC1D14 and enhance its functional activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A, a potent inhibitor of protein phosphatases PP1 and PP2A, maintains BC1D14 in an activated state by inhibiting its dephosphorylation. This direct interaction with BC1D14's phosphorylation state leads to its enhanced functional activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator. It enhances BC1D14 activity by activating JNK, which leads to the phosphorylation of BC1D14 and thus enhances its functional activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine is an adrenergic receptor agonist. It enhances BC1D14 activity by activating adrenergic receptors, which stimulate downstream signaling pathways leading to the phosphorylation and activation of BC1D14. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a CaMKII inhibitor. It enhances BC1D14 activity by stimulating compensatory signaling pathways through CaMKII inhibition, leading to the phosphorylation and activation of BC1D14. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 is a selective Akt inhibitor. It enhances BC1D14 activity by triggering compensatory signaling pathways through Akt inhibition, leading to the phosphorylation and activation of BC1D14. | ||||||